A Randomized Phase II Study of Metformin plus Paclitaxel/Carboplatin/Bevacizumab in Patients with Chemotherapy‐Naïve Advanced or Metastatic Nonsquamous Non‐Small Cell Lung Cancer

K. Marrone, Xian Zhou, P. Forde, M. Purtell, J. Brahmer, C. Hann, R. Kelly, B. Coleman, E. Gabrielson, G. Rosner, D. Ettinger

The oncologist, 2018

Retrospective clinical data and laboratory studies point to metformin having a potential role in cancer treatment; however, the efficacy of this drug in cancer treatment therapy has not been validated in prospective trials. In particular, limited data evaluating the effects of metformin in lung cancer has been available. Responding to this need, a prospective phase II clinical trial was conducted, and this article evaluates response rate and progression‐free survival of platinum‐based doublet chemotherapy with or without metformin in chemotherapy‐naïive advanced or metastatic nonsquamous non‐small cell lung cancer.

Cited by 37 publications.

Field of study: Medicine

10.1634/theoncologist.2017-0465